跳至主要内容
临床试验/NCT01827319
NCT01827319已完成不适用

A Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction

Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.24 个研究点 分布在 1 个国家目标入组 203 人开始时间: 2013年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
203
试验地点
24
主要终点
All Cause Mortality

研究概览

简要总结

The objectives of the registry are as follows:

  • Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System;
  • Further define the disease characteristics of the population being treated;
  • Examine transmyocardial revascularization (TMR) usage characteristics and 30-day outcomes;
  • Further assess the 30-day postoperative risk factors for adverse events. To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria are to be offered the opportunity to enroll in the study at participating centers.

详细描述

The objectives of this patient registry, which collects data on the Cardiogenesis Laser System, include: provide further information on the disease characteristics of the population being treated, examine TMR usage characteristics, monitor 30-day postoperative mortality and MACE rates, and assess preoperative and operative risk factors for adverse events.

To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria are to be offered the opportunity to enroll in the study at participating centers. Patient consent indicates approval to allow collection of their confidential data; nonetheless, their identity will not be disclosed in any publication of this study.

The primary endpoint to be assessed in this study is:

• All-cause 30-day mortality

Additional endpoints to be assessed in this study are:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Class IV angina (according to Canadian Cardiovascular Society Angina Scale)
  • Patients with regions of myocardium in the distal two-thirds of the left ventricle with reversible ischemia and who are not eligible for direct coronary revascularization (e.g., CABG or PTCA)

排除标准

  • Age less than18 years
  • Severely unstable angina (un-weanable from intravenous anti-anginals for 48-hours)

结局指标

主要结局

All Cause Mortality

时间窗: 30 days

Number of Participant Deaths

次要结局

  • Major Adverse Cardiovascular Events (MACE) Rate, Defined as the Incidence of Cardiac-related Death, Myocardial Infarction (Q-wave and Non Q-wave), Congestive Heart Failure, Cerebrovascular Accident, and Serious Arrhythmia(30 days)
  • 2 CCS Angina Class Reduction(30 days)

研究者

发起方
Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验

Cardiogenesis Transmyocardial Revascularization... | 临床试验